PALACE-1
Regimen
- Experimental
- preoperative pembrolizumab + carboplatin/paclitaxel + 41.4 Gy RT
Population
Resectable ESCC, any PD-L1 status
Key finding
pCR 55.6% (10/18 resected); G3+ AEs 65% (lymphopenia most common); no surgical delay; one treatment-related death (grade V AE).
Source: PMID 33373868